1st TRANSCAN-3 Joint Call 2021

Basic Information

JTC 2021: Next generation cancer immunotherapy: targeting the tumour microenvironment

Network TRANSCAN-3
Website https://transcan.eu/opencall.html
Aim of the joint call Despite advances in immunotherapies, obstacles and challenges, including limited response rates, the inability to predict clinical efficacy, and potential side effects such as autoimmune reactions or cytokine release syndromes, remain and hinder further applications of immunotherapies in clinics. Thus, a deeper understanding of the TME, able to dissect distinct classes and subclasses of it, is essential for deciphering new mechanisms of immunotherapies, defining new predictive biomarkers, and identifying novel therapeutic targets. In the context of translational research, this topic at the intersection of laboratory and clinical research in immuno-oncology will comprise two general aims: Aim 1: Identification and validation of TME subclasses and their contribution to the resistance mechanisms: Translational research using tumour samples collected from retrospective and/or prospective cohorts of patients. Aim 2: Targeting TME to improve efficacy of immunotherapy in human patients.
Type of joint call Two Stages - Call with pre-proposals and full proposals submissions
Launch date 06/04/2021
Deadline Pre-Proposal 29/06/2021 Submitted proposal: n/a
Deadline Full-Proposal 20/12/2021 Submitted proposal: n/a
Evaluation End Date 30/05/2022 Successful proposal: n/a Proposals funded: n/a
Is call co-funded? Yes
Call follow up funding
  • There are mechanisms in place to monitor
Call reasons
  • Achieving critical mass
  • Sharing competences and associated work
  • Addressing global issues
  • Developing common administrative procedures
  • Access to expertise from different countries
Research fields
  • Health
Type of research
  • Basic research
  • Applied Research
Target groups
  • Higher Education Institutions (HEIs)
  • Public Research Organisations (PROs)
  • Private and Semi-private Research and Technology Organisations (RTOs)
  • SME (Small and Medium Enterprises)
Participating networks n/a

Organisations Participating

Country Organisation
Austria Austrian Science Fund (FWF)
Belgium National Fund for Scientific Research (FNRS)
Belgium Research Foundation Flanders (FWO)
Canada Canadian Institutes of Health Research (CIHR)
Estonia Estonian Science Foundation (ETAG)
France ARC French foundation for Cancer Research (ARC-France)
France National Cancer Institute (INCa)
Germany Federal Ministry of Education and Research (BMBF)
Hungary National Research, Development and Innovation Office (NKFIH)
Ireland Health Research Board (HRB)
Israel Ministry of Health (CSO-MOH)
Italy Alliance Against Cancer (ACC)
Italy Ministry for Universities and Research (MUR)
Italy Ministry of Health (MOH/MDS)
Italy Tuscany Region (TOS)
Latvia State Education Development Agency (VIAA)
Norway Norwegian Cancer Society (NCS)
Norway Research Council of Norway (RCN)
Poland National Centre for Research and Development (NCBiR)
Portugal Foundation for Science and Technology (FCT)
Romania Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI)
Slovakia Slovak Academy of Science (SAS/SAV)
Spain Foundation for Asturias Promotion of Applied Scientific Research and Technology (FICYT)
Spain Institute of Health Carlos III (ISCIII)
Spain Spanish Association Against Cancer Scientific Foundation (AECC FC)
Turkey The Scientific and Technological Research Council of Turkey (TUBITAK)